LXRX Stock Summary and Trading Ideas (Lexicon Pharmaceuticals | NASDAQ:LXRX)

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.

As of May 12, 2026, LXRX stock price climbed to $2.41 with 5,976,173 million shares trading.

LXRX has a beta of -0.37, meaning it tends to be less sensitive to market movements. LXRX has a correlation of 0.00 to the broad based SPY ETF.

LXRX has a market cap of $1.07 billion. This is considered a Small Cap stock.

Last quarter Lexicon Pharmaceuticals reported $1 million in Revenue and $.00 earnings per share. This fell short of revenue expectation by $-8 million and exceeded earnings estimates by $.04.

In the last 3 years, LXRX traded as high as $3.73 and as low as $.28.

The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, VXF, SCHA, PRFZ, VHT.

LXRX has outperformed the market in the last year with a price return of +243.8% while the SPY ETF gained +32.1%. LXRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +75.9% and +42.6%, respectively, while the SPY returned +6.9% and +3.2%, respectively.

LXRX support price is $2.20 and resistance is $2.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.